ClinicalTrials.gov record NCT05760287
Echocardiographic Characterization of Cardiac Amyloidosis
Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This single-center observational study will analyze echocardiographic data from people with cardiac amyloidosis, using advanced techniques such as two- and three-dimensional speckle-tracking. It includes a retrospective phase (patients seen Jan 2020–Nov 2022) and a prospective phase (Dec 2022–Dec 2028). The study will compare echo measures over time and relate them to clinical outcomes.
What it is studying. The study is testing which echocardiographic features—including advanced strain imaging—help distinguish cardiac amyloidosis from other thickened-heart (hypertrophic) conditions, whether echocardiographic signs of myocardial damage change in people treated with tafamidis, and which echo measures predict adverse cardiovascular outcomes.
What the researchers hope to learn. To describe echo findings in cardiac amyloidosis using advanced echocardiography; to evaluate whether echo measures change after tafamidis treatment and correlate with clinical response; and to identify potential echocardiographic predictors of death or heart-failure hospitalization and major arrhythmias.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) will be enrolled. The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype. Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit.
Exclusion criteria
- missing data
- decline to the study participation
Study description and what participation involves
The registry record has no detailed description beyond the summary above.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
The study has a retrospective phase (reviewing clinical, electrocardiographic, and echocardiographic records from Jan 2020–Nov 2022) and a prospective phase (patients evaluated Dec 2022–Dec 2028). The registry requires participants to already have clinical, ECG, and echocardiographic data and at least one follow-up visit to be included. Study activities focus on echocardiography: reviewers will use standard and advanced techniques (two- and three-dimensional speckle-tracking) to measure heart function and will assess changes in echo parameters at 6 months and cardiovascular outcomes over 24 months. The record does not list other tests, blood or tissue collection, or a detailed visit schedule.
How the study is structured. An ambispective (both retrospective and prospective) single-center observational cohort study. Investigators will review and analyze echocardiographic measurements and follow-up data from enrolled patients; no experimental treatments are assigned by the study. Key timeframes in the registry include echo-parameter changes assessed at about 6 months and cardiovascular outcomes tracked up to 24 months.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- The registry lists this study under Cardiac Amyloidosis. Does it apply to my diagnosis?
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The listed sites are in Italy. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on ATTRv amyloidosis
This trial is also listed on this site under wild-type ATTR amyloidosis.
Important dates
- Study start
- Dec 9, 2022
- Primary completion
- Dec 2, 2030 (estimated)
- Study completion
- Feb 2, 2031 (estimated)
- Target enrollment
- 255 participants (estimated)
- Last updated on registry
- Sep 4, 2026
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Francesca Graziani, MD 📞 00390630154432 ✉ francesca.graziani@policlinicogemelli.it
- maria chiara meucci, MD 📞 00390630154432 ✉ mariachiara.meucci@guest.policlinicogemelli.it
Participating sites (1)
- Fondazione Policlinico Gemelli IRCCSRecruiting
Roma, RM, 00168 · Italy
- francesca graziani, MD · +31 3313957433 · francesca.graziani@policlinicogemelli.it
- maria chiara meucci, MD · + 31 3313957433 · mariachiara.meucci@guest.policlinicogemelli.it
Terms used on this page · explanations by MedicalUpdates.ai
- echocardiography
- An ultrasound scan of the heart. A transesophageal echocardiogram is done through a probe passed into the food pipe for a closer view.
- follow-up
- The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials